TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07705555: A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 960 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$1,178,600

Rescue Site Savings

+$754,304

Unlock Full NCT07705555 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07705555 Rescue Dossier →